Ligand validation:8DSF

TO0: (4S)-4-[2-(2-{4-[(2E)-4-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}-4-oxobut-2-en-1-yl]piperazin-1-yl}ethoxy)acetamido]-1-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-L-prolinamide unbound form

TO0 is a Ligand Of Interest in 8DSF designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8DSF_TO0_A_402	89%	71%	0.08	0.959	0.46	0.65	1	3	0	0	100%	1
8DSF_TO0_B_402	87%	70%	0.084	0.956	0.45	0.69	1	3	0	0	100%	1
8DSF_TO0_D_402	23%	70%	0.139	0.856	0.25	0.86	-	2	0	0	47%	0.4691
8DSF_TO0_C_402	15%	77%	0.166	0.821	0.21	0.68	-	1	0	0	47%	0.4691

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.